Preparation and subsequent degradation of poly(l-lactic acid) microspheres suitable for aerosolisation: a physico-chemical study

El-Baseir, Mokhtar M; Phipps, Mark A.; Kellaway, I.W.

doi:10.1016/s0378-5173(96)04873-9

Cited by 18 publications

(7 citation statements)

References 11 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Numerous examples of sustained-release microspheres for pulmonary delivery are documented in the literature, e.g., isoproterenol PLGA microspheres (208), nedocromil sodium/ beclomethasone dipropionate PLA microspheres, etc. (209). These microspheres were produced to a suitable size for aerosolization (209) and were successfully tested for sustained release/action in vitro and/or in vivo (208).…”

Section: Emulsion-based Methodsmentioning

confidence: 99%

See 1 more Smart Citation

Particle Engineering for Pulmonary Drug Delivery

et al. 2007

View full text Add to dashboard Cite

With the rapidly growing popularity and sophistication of inhalation therapy, there is an increasing demand for tailor-made inhalable drug particles capable of affording the most efficient delivery to the lungs and the most optimal therapeutic outcomes. To cope with this formulation demand, a wide variety of novel particle technologies have emerged over the past decade. The present review is intended to provide a critical account of the current goals and technologies of particle engineering for the development of pulmonary drug delivery systems. These technologies cover traditional micronization and powder blending, controlled solvent crystallization, spray drying, spray freeze drying, particle formation from liquid dispersion systems, supercritical fluid processing and particle coating. The merits and limitations of these technologies are discussed with reference to their applications to specific drug and/or excipient materials. The regulatory requirements applicable to particulate inhalation products are also reviewed briefly.

show abstract

Section: Emulsion-based Methodsmentioning

confidence: 99%

“…(209). These microspheres were produced to a suitable size for aerosolization (209) and were successfully tested for sustained release/action in vitro and/or in vivo (208).…”

Section: Emulsion-based Methodsmentioning

confidence: 99%

Particle Engineering for Pulmonary Drug Delivery

et al. 2007

View full text Add to dashboard Cite

show abstract

“…By this method, biodegradable polymers, including poly(l-lactic acid) (PLA), poly(glycolic) acid (PGA), and poly(lactide-co-glycolide) acid (PLGA), have been intensively investigated as carriers for solid drug nanoparticles. 167 …”

Section: Double Emulsion/solvent Evaporation Techniquementioning

confidence: 99%

Nanomedicine in pulmonary delivery

Mansour¹,

Rhee²,

Wu³

2009

IJN

405

269

View full text Add to dashboard Cite

“…Microspheres are less hygroscopic and are thus less liable to swell in the presence of moisture located in the lungs [334].…”

Section: Microparticles and Nanoparticlesmentioning

confidence: 99%

Drug-Loaded Nanocarriers: Passive Targeting and Crossing of Biological Barriers

Rabanel

Aoun²,

Elkin³

et al. 2012

CMC

160

View full text Add to dashboard Cite

Poor bioavailability and poor pharmacokinetic characteristics are some of the leading causes of drug development failure. Therefore, poorly-soluble drugs, fragile proteins or nucleic acid products may benefit from their encapsulation in nanosized vehicles, providing enhanced solubilization, protection against degradation, and increased access to pathological compartments. A key element for the success of drug-loaded nanocarriers is their ability to either cross biological barriers themselves, or allow loaded drugs to traverse them to achieve optimal pharmacological action at pathological sites. Depending on the mode of administration, nanocarriers may have to cross different physiological barriers in their journey towards their target. In this review, the crossing of biological barriers by passive targeting strategies will be presented for intravenous delivery (vascular endothelial lining, particularly for tumor vasculature and blood brain barrier targeting), oral administration (gastrointestinal lining), and upper airway administration (pulmonary epithelium). For each specific barrier, background information will be provided on the structure and biology of the tissues involved as well as available pathways for nano-objects or loaded drugs (diffusion and convection through fenestration, transcytosis, tight junction crossing, etc.). The determinants of passive targeting - size, shape, surface chemistry, surface patterning of nanovectors - will be discussed in light of current results. Perspectives on each mode of administration will be presented. The focus will be on polymeric nanoparticles and dendrimers, although advances in liposome technology will be also reported as they represent the largest body in the drug delivery literature.

show abstract

Preparation and subsequent degradation of poly(l-lactic acid) microspheres suitable for aerosolisation: a physico-chemical study

Cited by 18 publications

References 11 publications

Particle Engineering for Pulmonary Drug Delivery

Particle Engineering for Pulmonary Drug Delivery

Nanomedicine in pulmonary delivery

Drug-Loaded Nanocarriers: Passive Targeting and Crossing of Biological Barriers

Contact Info

Product

Resources

About